Infigo Lifesciences Private Limited, a active private limited company, was established on 26 September 2017 in Mumbai, Maharashtra, India. Engaging in eye care & ophthalmology clinics within the hospital and medical care sector, it holds CIN: U74999MH2017PTC300119. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹14.62 Cr and a paid-up capital of ₹7.83 M.
It upholds a compliant status. Employing 98 professional, Its leadership includes Shridhar Thakur Raghunath (Managing Director), Anil Vasudev Kamath (Director). Past directors included Prashasta Seth, Nidhi Ghuman, Vikrant Balbir Sibal. Its latest AGM occurred on 29 August 2025, with the balance sheet filed on 31 March 2025. It is based at Office No.103 1St Flr., Terminal 9, Nehru Road Near Vile Parle Police Station, Vile Par, Le (East), Mumbai, Maharashtra, 400057.
U74999MH2017PTC300119
300119
26 September 2017
₹14.62 Cr
₹7.83 M
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Infigo Lifesciences Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shridhar Thakur Raghunath | Managing Director | 26 Sep 2017 | Current |
| Anil Vasudev Kamath | Director | 26 Sep 2017 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Nominee Director | 31 Dec 2020 | Past |
| Pramod Abcsdd | Nominee Director | 02 May 2024 | Past |
| Pramod Abcsdd | Nominee Director | 02 Nov 2021 | Past |
| Pramod Abcsdd | Director | 07 Aug 2018 | Past |
| Pramod Abcsdd | Director | 06 Aug 2018 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Infigo Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 20.36% increase. The company also saw a substantial fall in profitability, with a 241.61% decrease in profit. The company's net worth Soared by an impressive increase of 102.01%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Infigo Lifesciences had a public holding of 10.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Infigo Lifesciences has a workforce of 98 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Infigo Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Infigo Lifesciences's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Infigo Lifesciences Private Limited last Annual general meeting of members was held on 29 Aug 2025 as per latest MCA records. was completed.
Progress on Infigo Lifesciences Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was documented.
The activity Shridhar Thakur Raghunath was appointed as a CEO was appointed as a CEO on 07 Aug 2018 & has been associated with this company since 7 years 4 months . was completed.
The activity Shridhar Thakur Raghunath was appointed as a Managing Director was appointed as a Managing Director on 26 Sep 2017 & has been associated with this company since 8 years 2 months . was completed.
The activity Anil Vasudev Kamath was appointed as a Director was appointed as a Director on 26 Sep 2017 & has been associated with this company since 8 years 2 months . was completed.
The activity Infigo Lifesciences Private Limited was registered on 26 Sep 2017 with Roc Mumbai & aged 8 years 2 months as per MCA records. was completed.
Hearing Solution (Hearzap), a chain of audiology stores in Hyderabad, has raised Rs 50 crore (roughly $6 million) in a Series A round from 360 One Healthcare Opportunities Fund, a private equity (PE).
The CIN of Infigo Lifesciences Private Limited is U74999MH2017PTC300119.
Infigo Lifesciences Private Limited is headquartered at Office No.103 1St Flr., Terminal 9, Nehru Road Near Vile Parle Police Station, Vile Par, Le (East), Mumbai, Maharashtra, 400057.
Infigo Lifesciences Private Limited was incorporated on 26 September 2017.
The current directors of Infigo Lifesciences Private Limited are
The primary industry of Infigo Lifesciences Private Limited is Hospital And Medical Care.
Infigo Lifesciences Private Limited is unlisted.
The authorized capital of Infigo Lifesciences Private Limited is ₹14.62 Cr, and the paid-up capital is ₹7.83 M.
The compliance status of Infigo Lifesciences Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX